In a regulatory filing, Prelude Therapeutics (PRLD) disclosed that its CEO Krishna Vaddi bought 675K shares of common stock on March 25th in a total transaction size of $467K.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD: